ABSTRACT
Pancreatic cancer is one of the deadliest malignancies in humans and it is expected to play a bigger part in cancer burden in the years to come. Pancreatic ductal adenocarcinoma (PDAC) represents 85% of all primary pancreatic malignancies. Recently, much attention has been given to PDAC, with significant advances in the understanding of the mechanisms underpinning disease initiation and progression, along with noticeable improvements in overall survival in both localized and metastatic settings. However, given their rarity, rare histological subtypes of pancreatic cancer have been underappreciated and are frequently treated as PDAC, even though they might present non-overlapping molecular alterations and clinical behavior. While some of these rare histological subtypes are true variants of PDAC that should be treated likewise, others represent separate clinicopathological entities, warranting a different therapeutic approach. In this review, we highlight clinical, pathological, and molecular aspects of rare histological types of pancreatic cancer, along with the currently available data to guide treatment decisions.
Should rare subtypes of pancreatic cancer be treated as its most common variant (ductal adenocarcinoma)? The most common type of pancreatic cancer is ductal adenocarcinoma. While much attention has been given to the molecular aspects and treatment aspects of this disease, rare variants of pancreatic cancer have been underappreciated. Some of them present unique molecular features that suggest different treatment approaches could lead to better outcomes. In this review, we summarize information on the clinical, pathological, and molecular features of rare subtypes of pancreatic cancer, along with subtype-specific data on treatment.
ABSTRACT
Gastric cancer (GC) remains a formidable global health challenge, ranking among the top-five causes of cancer-related deaths worldwide. The majority of patients face advanced stages at diagnosis, with a mere 6% five-year survival rate. First-line treatment for metastatic GC typically involves a fluoropyrimidine and platinum agent combination; yet, predictive molecular markers have proven elusive. This review navigates the evolving landscape of GC biomarkers, with a specific focus on Claudin 18.2 (CLDN18.2) as an emerging and promising target. Recent phase III trials have unveiled the efficacy of Zolbetuximab, a CLDN18.2-targeting antibody, in combination with oxaliplatin-based chemotherapy for CLDN18.2-positive metastatic GC. As this novel therapeutic avenue unfolds, understanding the nuanced decision making regarding the selection of anti-CLDN18.2 therapies over other targeted agents in metastatic GC becomes crucial. This manuscript reviews the evolving role of CLDN18.2 as a biomarker in GC and explores the current status of CLDN18.2-targeting agents in clinical development. The aim is to provide concise insights into the potential of CLDN18.2 as a therapeutic target and guide future clinical decisions in the management of metastatic GC.
ABSTRACT
Experiência de equipe multiprofissional realizando atividade em grupo focada na saúde do homem em que acreditamos ser possível promover prevenção, educação e diagnóstico de agravos de relevância epidemiológica e ao mesmo tempo acolher e vincular essa parcela da população no serviço de saúde (AU)
Subject(s)
Humans , Male , Adolescent , Young Adult , Adult , Middle Aged , Aged , Aged, 80 and over , Men's Health , National Health Strategies , Unified Health SystemABSTRACT
Experiência de equipe multiprofissional realizando atividade em grupo focada na saúde do homem em que acreditamos ser possível promover prevenção, educação e diagnóstico de agravos de relevância epidemiológica e ao mesmo tempo acolher e vincular essa parcela da população no serviço de saúde
Subject(s)
Male , Humans , Adolescent , Young Adult , Adult , Middle Aged , Aged , Aged, 80 and over , Men's Health , National Health Strategies , Unified Health SystemABSTRACT
Experiência de equipe multiprofissional realizando atividade em grupo focada na saúde do homem em que acreditamos ser possível promover prevenção, educação e diagnóstico de agravos de relevância epidemiológica e ao mesmo tempo acolher e vincular essa parcela da população no serviço de saúde.